A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

Yung, W K A, Albright, R E, Olson, J, Fredericks, R, Fink, K, Prados, M D, Brada, M, Spence, A, Hohl, R J, Shapiro, W, Glantz, M, Greenberg, H, Selker, R G, Vick, N A, Rampling, R, Friedman, H, Phillips, P, Bruner, J, Yue, N, Osoba, D, Zaknoen, S, Levin, V A·2000·British Journal of Cancer
DOI 10.1054/bjoc.2000.1316

Cited by (928)

Items 401–500 of 928

  1. A Multicenter Cohort Study of Dose-Dense Temozolomide (21 of 28 Days) for the Treatment of Recurrent Anaplastic Astrocytoma or Oligoastrocytoma
    Bart Neyns, C. Chaskis, Eric J. Joosens, Johan J Menten, Lionel A. D'Hondt, Fabrice Branle, Jan Sadones, Alex Michotte · 2008 · Cancer Investigation
  2. Temozolomide: realizing the promise and potential
    Ramamoorthy Nagasubramanian, M. Eileen Dolan · 2003 · Current Opinion in Oncology
  3. The effectiveness and cost-effectiveness of temozolomide for the treatment of recurrent malignant glioma: a rapid and systematic review
    Jacqueline Dinnes, C Cave, Shuiqing Huang, K. Major, Ruairidh Milne · 2001 · Health Technology Assessment
  4. Malignant gliomas: old and new systemic treatment approaches
    Tanja Mesti, Janja Ocvirk · 2015 · Radiology and Oncology
  5. The Emerging Role of Anti-Angiogenic Therapy for Malignant Glioma†
    David A. Reardon, Annick Desjardins, Jeremy N. Rich, James J. Vredenburgh · 2008 · Current Treatment Options in Oncology
  6. Carboplatin and bevacizumab for recurrent malignant glioma
    Maciej M. Mrugała, LAURIE K. CREW, James R. Fink, Alexander M. Spence · 2012 · Oncology Letters
  7. Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients
    Antonio Silvani, E. Lamperti, Paola Gaviani, Marica Eoli, Anna Fiumani, Andrea Salmaggi, Chiara Falcone, Graziella Filippini, A. Botturi, Amerigo Boiardi · 2007 · Journal of Neuro-Oncology
  8. Transforming growth factor-beta: A target for cancer therapy
    Ronan Joseph Kelly, John Charles Morris · 2009 · Journal of Immunotoxicology
  9. Irinotecan and bevacizumab in recurrent glioblastoma multiforme
    Jan Nyrop Jakobsen, Benedikte Hasselbalch, Marie‐Thérése Stockhausen, Ulrik Lassen, Hans Skovgaard Poulsen · 2011 · Expert Opinion on Pharmacotherapy
  10. The role of radiation in treating glioblastoma: here to stay
    Christopher D. Corso, Ranjit S. Bindra, Minesh P. Mehta · 2017 · Journal of Neuro-Oncology
  11. An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting
    Athanassios P. Kyritsis, Victor A. Levin · 2011 · Cancer Chemotherapy and Pharmacology
  12. Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment
    Mélanie Philippon, Isabelle Morange, Marilyne Barrie, Anne Barlier, David Taïeb, Henry Dufour, Bernard Conte‐Devolx, Thierry Christian Brue, Frédéric Castinetti · 2012 · Annales d Endocrinologie
  13. Bevacizumab: A Treatment Option for Recurrent Glioblastoma Multiforme
    Larry W. Buie, John M Valgus · 2008 · Annals of Pharmacotherapy
  14. Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates
    Lijo Simpson, Evanthia Galanis · 2006 · Expert Review of Anticancer Therapy
  15. A novel treatment for glioblastoma: integrin inhibition
    Marc Charles Chamberlain, Timothy Cloughsey, David A. Reardon, Patrick Yung Wen · 2012 · Expert Review of Neurotherapeutics
  16. Virotherapy against malignant glioma stem cells
    Mahua Dey, Ilya V. Ulasov, Maciej S. Lesniak · 2009 · Cancer Letters
  17. A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma
    Mark R. Gilbert, Javier Gonzalez, Kathy Hunter, Kenneth R. Hess, Pierre Giglio, E. Chang, Vinay K. Puduvalli, Morris D. Groves, Howard Colman, C. Conrad et al. · 2010 · Neuro-Oncology
  18. Cost of temozolomide therapy and global care for recurrent malignant gliomas followed until death
    Jean-Blaise Wasserfallen, Sandrine Ostermann, Serge Leyvraz, Roger Stupp · 2005 · Neuro-Oncology
  19. Temozolomide: The evidence for its therapeutic efficacy in malignant astrocytomas
    Warren P. Mason · 2009 · Core evidence
  20. Frequently asked questions in the medical management of high-grade glioma: a short guide with practical answers
    Roger Stupp, Andreas Felix Hottinger, Martin J. van den Bent, PY Dietrich, Alba Ariela Brandes · 2008 · Annals of Oncology
  21. Phase II study of temozolomide and cisplatin as primary treatment prior to radiotherapy in newly diagnosed glioblastoma multiforme patients with measurable disease. A study of the Spanish Medical Neuro-Oncology Group (GENOM)
    Carmen Balañá, Antonio Lopez Pousa, Alfonso Berrocal, Ricardo Yayá, Ana Herrero, Jose-luis Garc�a, Javier Martín‐Broto, Manuel Benavides, Miguel Cerd�-nicol�s, R. Ballester et al. · 2004 · Journal of Neuro-Oncology
  22. Is protracted low-dose temozolomide feasible in glioma patients?
    A. Tosoni, G. Cavallo, Mario Ermani, Luciano Scopece, Enrico Franceschi, Claudio Ghimenton, Marina Paola Gardiman, Lara Maria Pasetto, Valeria Blatt, Alba Ariela Brandes · 2006 · Neurology
  23. Treatment of recurrent high-grade gliomas
    Patrick Yung Wen, Alba Ariela Brandes · 2009 · Current Opinion in Neurology
  24. Second-line chemotherapy with dacarbazine and fotemustine in nitrosourea-pretreated patients with recurrent glioblastoma multiforme
    Barbara Fazeny-Dörner, Mario Veitl, Catharina Wenzel, Maria Piribauer, Karl Rössler, Karin Dieckmann, Karl Ungersböck, Christine Marosi · 2003 · Anti-Cancer Drugs
  25. UKT-04 trial of continuous metronomic low-dose chemotherapy with methotrexate and cyclophosphamide for recurrent glioblastoma
    Ulrich Herrlinger, Johannes Rieger, Joachim Peter Steinbach, Thomas N�gele, JOHANNES DICHGANS, Michael Weller · 2005 · Journal of Neuro-Oncology
  26. Formation of DNA adducts and induction of lacI mutations in Big Blue Rat-2 cells treated with temozolomide: implications for the treatment of low-grade adult and pediatric brain tumors.
    William J. Bodell, Nilesh W Gaikwad, Douglas L. Miller, Mitchel Stuart Berger · 2003 · PubMed
  27. The role of targeted therapies in the management of progressive glioblastoma
    Jeffrey J. Olson, Lakshmi Nayak, David Ryan Ormond, Patrick Yung Wen, Steven N. Kalkanis, Timothy Charles Ryken · 2014 · Journal of Neuro-Oncology
  28. Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma
    Ufuk Abacıoğlu, Hale Başak Çağlar, Perran Fulden Yumuk, Züleyha Akgün, Beste M. Atasoy, Meriç Şengöz · 2010 · Journal of Neuro-Oncology
  29. Glioblastoma multiforme: evidence-based approach to therapy
    Martin Kelly Nicholas · 2007 · Expert Review of Anticancer Therapy
  30. Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study
    Walter Taal, Joyce Segers-van Rijn, Johan M. Kros, Irene van Heuvel, Carin C.D. van der Rijt, Jacoline E. C. Bromberg, Peter A.E. Sillevis Smitt, Martin J. van den Bent · 2012 · Journal of Neuro-Oncology
  31. Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma
    Shlomit Yust‐Katz, Diane Liu, Ying Yuan, Vivien Liu, Sanghee Kang, Morris D. Groves, Vinay K. Puduvalli, Victor A. Levin, Charles A. Conrad, Howard Colman et al. · 2013 · Cancer
  32. The efficacy and safety of various dose-dense regimens of temozolomide for recurrent high-grade glioma: a systematic review with meta-analysis
    Wei Wei, Xin Chen, Ximeng Ma, Dawei Wang, Zongze Guo · 2015 · Journal of Neuro-Oncology
  33. A phase II EORTC study of temozolomide in patients with malignant pleural mesothelioma
    Jan P. van Meerbeeck, P. Baas, C. Debruyne, Egbert Frederik Smit, Rob J. van Klaveren, Danny Galdermans, M.A. Lentz, Chris Manegold, Giuseppe Giaccone · 2002 · European Journal of Cancer
  34. Current and Investigational Drug Strategies for Glioblastoma
    M. Ajaz, Sarah Jefferies, L. Brazil, Colin Watts, Anthony J. Chalmers · 2014 · Clinical Oncology
  35. Neoadjuvant phase II multicentre study of new agents in patients with malignant glioma after minimal surgery. Report of a cohort of 187 patients treated with temozolomide
    Michael Brada, Sue E. Ashley, Anna Dowe, Adam Gonsalves, A. Huchet, Gianfranco Angelo Pesce, Michele Reni, Frank H. Saran, B. Wharram, M. Wilkins et al. · 2005 · Annals of Oncology
  36. G2/M inhibitors as pharmacotherapeutic opportunities for glioblastoma: the old, the new, and the future
    Angel Maurício Castro‐Gamero, Alejandra Pezuk Julia, Sol Brassesco María, Luíz Gonzaga Tone · 2018 · Cancer Biology and Medicine
  37. Can we afford to add chemotherapy to radiotherapy for glioblastoma multiforme? Cost‐identification analysis of concomitant and adjuvant treatment with temozolomide until patient death
    Jean‐Blaise Wasserfallen, Sandrine Ostermann, Alessia Pica, René‐Olivier Mirimanoff, Serge Leyvraz, Jean‐Guy Villemure, Roger Stupp · 2004 · Cancer
  38. Temozolomide-induced partial response in a patient with primary diffuse leptomeningeal gliomatosis
    Enrico Franceschi, Giovanna Cavallo, Luciano Scopece, Roberta Degli Esposti, Gabriele Paioli, Anna Paioli, Emanuela Palmerini, Maria Pia Foschini, Anna Federica Marliani, Lucio Crinò · 2005 · Journal of Neuro-Oncology
  39. Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors
    Karina Vera, Latifa Djafari, Sandrine J. Faivre, Jean‐Sébastien Guillamo, Kamel Djazouli, M. Osorio, Fabrice Parker, C Cioloca, Bassam Abdulkarim, Jean‐Pierre Armand et al. · 2003 · Annals of Oncology
  40. Phase II study of ifosfamide, carboplatin, and etoposide in patients with a first recurrence of glioblastoma multiforme
    Tomokazu Aoki, Tomohiko Mizutani, Kuniharu Nojima, Takehisa Takagi, Ryosuke Okumura, Yoshiaki Yuba, Tetsuya Ueba, Jun A. Takahashi, Shin‐Ichi Miyatake, Kazuhiko Nozaki et al. · 2009 · Journal of neurosurgery
  41. Toward Personalized Targeted Therapeutics: An Overview
    Shiao-Pei S. Weathers, Mark R. Gilbert · 2016 · Neurotherapeutics
  42. Overcoming Therapeutic Resistance in Malignant Gliomas: Current Practices and Future Directions
    Arnab Chakravarti, Kamalakannan Palanichamy · 2007 · Cancer treatment and research
  43. Promising survival in patients with high-grade gliomas following therapy with a novel boronated porphyrin
    Mark Andrew Rosenthal, Bhadu Kavar, Shannon C. Uren, Andrew Henry Kaye · 2003 · Journal of Clinical Neuroscience
  44. Pegylated Liposomal Doxorubicin in Recurrent Malignant Glioma: Analysis of a Case Series
    Glas, Martin, Koch, Horst, Hirschmann, Birgit, Jauch, Tanja, Steinbrecher, Andreas, Herrlinger, Ulrich, Bogdahn, Ulrich, Hau, Peter · 2007 · Oncology
  45. Limited impact of prognostic factors in patients with recurrent glioblastoma multiforme treated with a bevacizumab-based regimen
    Émeline Tabouret, Maryline Barrié, A. Thiebaut, M. Matta, Céline Boucard, Didier Autran, Anderson Loundou, Olivier Louis Chinot · 2013 · Journal of Neuro-Oncology
  46. The future of high-grade glioma: Where we are and where are we going
    Marc Charles Chamberlain, Émilie Le Rhun, Sophie Taillibert · 2015 · Surgical Neurology International
  47. Challenges and Perspectives of Standard Therapy and Drug Development in High-Grade Gliomas
    Shalini Sundramurthi Chelliah, Ervin Ashley Lourdes Paul, Muhamad Noor Alfarizal Kamarudin, Ishwar S. Parhar · 2021 · Molecules
  48. Antiangiogenic Strategies for Treatment of Malignant Gliomas
    Andrew S. Chi, Andrew David Norden, Patrick Yung Wen · 2009 · Neurotherapeutics
  49. Angiogenic inhibition in high-grade gliomas: past, present and future
    Jasmin Jo, David Schiff, Benjamin W. Purow · 2012 · Expert Review of Neurotherapeutics
  50. Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma
    Tobias Walbert, Mark R. Gilbert, Morris D. Groves, Vinay K. Puduvalli, W.K. Alfred Yung, Charles A. Conrad, George C. Bobustuc, Howard Colman, Sigmund H. Hsu, Benjamin Nebiyou Bekele et al. · 2010 · Journal of Neuro-Oncology
  51. Therapy for recurrent malignant glioma in adults
    Maciej M. Mrugała, Santosh Kesari, Naren Raj Ramakrishna, Patrick Yung Wen · 2004 · Expert Review of Anticancer Therapy
  52. Factors predicting temozolomide induced clinically significant acute hematologic toxicity in patients with high-grade gliomas: A clinical audit
    Tejpal Gupta, Sarthak Mohanty, Aliasgar V. Moiyadi, Rakesh Jalali · 2013 · Clinical Neurology and Neurosurgery
  53. Temozolomide as Second-line Chemotherapy for Relapsed Gliomas
    S. Trent, Anthony H. Kong, Susan C Short, Daphne Traish, S. Ashley, Anna Dowe, Frances Hines, Michael Brada · 2002 · Journal of Neuro-Oncology
  54. A multidrug combination designed for reversing resistance to BCNU in glioblastoma multiforme
    Alba Ariela Brandes, Sergio Turazzi, Umberto Basso, Lara Maria Pasetto, Bianca Guglielmi, Lorenzo Volpin, Paolo Iuzzolino, Pietro Amistà, Gian Domenico Pinna, Renato Scienza et al. · 2002 · Neurology
  55. Carboplatin Chemotherapy in Patients with Recurrent High-grade Glioma
    Louise Janet Murray, Caroline H. Bridgewater, D. Levy · 2010 · Clinical Oncology
  56. Pivotal therapeutic trials for infiltrating gliomas and how they affect clinical practice
    Rimas Vincas Lukas, Maciej M. Mrugała · 2016 · Neuro-Oncology Practice
  57. Pharmacology of Oral Chemotherapy Agents
    Ann Birner · 2003 · Clinical journal of oncology nursing
  58. DNA ligase IV as a new molecular target for temozolomide
    Natsuko Kondo, Akihisa Takahashi, Eiichiro Mori, Ken Ohnishi, Peter J. McKinnon, Toshisuke Sakaki, Hiroyuki Nakase, Takeo Ohnishi · 2009 · Biochemical and Biophysical Research Communications
  59. Update on bevacizumab and other angiogenesis inhibitors for brain cancer
    Mikael L. Rinne, Eudocia Q. Lee, Lakshmi Nayak, Andrew David Norden, Rameen Beroukhim, Patrick Yung Wen, David A. Reardon · 2013 · Expert Opinion on Emerging Drugs
  60. Success and Failures of Combined Modalities in Glioblastoma Multiforme: Old Problems and New Directions
    Christopher D. Corso, Ranjit S. Bindra · 2016 · Seminars in Radiation Oncology
  61. Cyclooxygenase-2 expression in astrocytes and microglia in human oligodendroglioma and astrocytoma
    Şehime Gülsün Temel, Zeynep Kahveci · 2009 · Journal of Molecular Histology
  62. Impact of combination therapy with repeat surgery and temozolomide for recurrent or progressive glioblastoma multiforme: a prospective trial
    Mizuhiko Terasaki, Etsuyo Ogo, Shintaro Fukushima, Kiyohiko Sakata, Naohisa Miyagi, Toshi Abe, Minoru Shigemori · 2007 · Surgical Neurology
  63. Immune checkpoints and cancer in the immunogenomics era
    Ryan M. Park, Mary Winnicki, Evan Liu, Wen‐Ming Chu · 2018 · Briefings in Functional Genomics
  64. Economic Evaluation of Temozolomide in the Treatment of Recurrent Glioblastoma Multiforme
    Janne A. Martikainen, Akseli Kivioja, Taru Hallinen, Pia Vihinen · 2005 · PharmacoEconomics
  65. Therapeutic Advances in Malignant Glioma: Current Status and Future Prospects
    H. Ian Robins, Andrew B. Lassman, Deepak Khuntia · 2009 · Neuroimaging Clinics of North America
  66. Improved Median Survival for Glioblastoma Multiforme Following Introduction of Adjuvant Temozolomide Chemotherapy
    Michael Back, Emily LL Ang, Wai-Hoe Ng, Siew-Ju See, C. C. Tchoyoson Lim, SP Chan, Tseng-Tsai Yeo · 2007 · Annals of the Academy of Medicine Singapore
  67. Valproic acid-induced amphiregulin secretion confers resistance to temozolomide treatment in human glioma cells
    Jui‐Chieh Chen, I‐Neng Lee, Cheng Huang, Yuping Wu, Chiu‐Yen Chung, Ming‐Hsueh Lee, Martin Hsiu‐Chu Lin, Jen‐Tsung Yang · 2019 · BMC Cancer
  68. Treatment of astrocytomas
    Javier Gonzalez, Mark R. Gilbert · 2005 · Current Opinion in Neurology
  69. Temozolomide in combination with other cytotoxic agents
    Mike Prados · 2001 · Seminars in Oncology
  70. Novel chemotherapeutics and other therapies for treating high-grade glioma
    Jennifer H. Kang, Cory Adamson · 2015 · Expert Opinion on Investigational Drugs
  71. Pharmacotherapies for the treatment of glioblastoma – current evidence and perspectives
    Katharina Seystahl, Dorothee Gramatzki, Patrick Roth, Michael Weller · 2016 · Expert Opinion on Pharmacotherapy
  72. Efficacy of Temozolomide Is Correlated With 1p Loss and Methylation of the Deoxyribonucleic Acid Repair Gene MGMT in Malignant Gliomas
    Dai Ishii, Atsushi Natsume, Toshihiko Wakabayashi, Hisashi Hatano, Yoshio Asano, Hiroki TAKEUCHI, Shinji Shimato, Motokazu Ito, Masazumi Fujii, Jun Yoshida · 2007 · Neurologia medico-chirurgica
  73. Phase 1 trial of temozolomide plus irinotecan plus O6‐benzylguanine in adults with recurrent malignant glioma
    Jennifer A. Quinn, Xiaoyin “Sara” Jiang, David A. Reardon, Annick Desjardins, James J. Vredenburgh, Sridharan Gururangan, John Howard Sampson, Roger E. McLendon, James E. Herndon, Henry S. Friedman · 2009 · Cancer
  74. Molecular characteristics of pediatric non-ependymal, non‑pilocytic gliomas associated with resistance to temozolomide
    Hikaru Sasaki · 2011 · Molecular Medicine Reports
  75. Leptomeningeal dissemination of cerebellar malignant astrocytomas
    Hidenori Endo, Toshihiro Kumabe, Hidefumi Jokura, Reizo Shirane, Hisanori Ariga, Yoshihisa Takai, Takashi Yoshimoto · 2003 · Journal of Neuro-Oncology
  76. Indicators of Functional Status for Primary Malignant Brain Tumour Patients
    Miguel Bussière, Wilma M. Hopman, Andrew G. Day, Alicia Paris Pombo, Teresa Neves, Francisco Espinosa · 2005 · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
  77. The use of temozolomide in recurrent malignant gliomas
    Andrew M. Gaya, Jeremy H. Rees, Anita Greenstein, Justin Stebbing · 2002 · Cancer Treatment Reviews
  78. Recent Medical Management of Glioblastoma
    Derek Richard Johnson, Susan Marina Chang · 2012 · Advances in experimental medicine and biology
  79. Should Biomarkers Be Used to Design Personalized Medicine for the Treatment of Glioblastoma?
    Michael Weller, Wolfgang Wick, Monika E. Hegi, Roger Stupp, Ghazaleh Tabatabai · 2010 · Future Oncology
  80. Personalized Treatment for a Patient With aBRAFV600E Mutation Using Dabrafenib and a Tumor Treatment Fields Device in a High-Grade Glioma Arising From Ganglioglioma
    Silviya K. Meletath, Dean C. Pavlick, Timothy J. Brennan, Roy H. Hamilton, Juliann Chmielecki, Julia Andrea Elvin, Norma Alonzo Palma, Jeffrey S. Ross, Vincent A. Miller, Philip J. Stephens et al. · 2016 · Journal of the National Comprehensive Cancer Network
  81. Reduced EGFR and increased miR-221 is associated with increased resistance to temozolomide and radiotherapy in glioblastoma
    Zammam Areeb, Sarah F. Stuart, Alice J. West, Juliana Gomez, Hong P. T. Nguyen, Lucia Paradiso, Ahmad Zulkifli, Jordan Jones, Andrew Henry Kaye, Andrew P. Morokoff et al. · 2020 · Scientific Reports
  82. Central Nervous System Tumors
    Ashwatha Narayana, Lawrence David Recht, Philip H. Gutin · 2010 · Elsevier eBooks
  83. Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy
    Jeffrey J. Raizer, Mark Gordon Malkin, Martin Kleber, Lauren E. Abrey · 2004 · Neuro-Oncology
  84. Malignant gliomas
    Patrick Yung Wen, Santosh Kesari · 2004 · Current Neurology and Neuroscience Reports
  85. Brazilian marine sponge Polymastia janeirensis induces apoptotic cell death in human U138MG glioma cell line, but not in a normal cell culture
    Mário Luiz Conte da Frota, Elizandra Braganhol, Andrés Delgado Cañedo, Fábio Klamt, Miriam Anders Apel, Beatriz Mothes B, Cléa Beatriz Lerner, Ana Maria Oliveira Battastini, Amélia Teresinha Henriques, José Cláudio Fonseca Moreira · 2008 · Investigational New Drugs
  86. Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma
    Surasak Phuphanich, Kathryn A. Carson, Stuart A. Grossman, Glenn Jay Lesser, Jeffrey J. Olson, Tom Mikkelsen, Serena Desideri, Joy D. Fisher · 2008 · Neuro-Oncology
  87. Recurrent high-grade glioma: a diagnostic and therapeutic challenge
    Tobias Walbert, Tom Mikkelsen · 2011 · Expert Review of Neurotherapeutics
  88. NETRIN-4 Protects Glioblastoma Cells FROM Temozolomide Induced Senescence
    Li Li, Yizhou Hu, Irene Ylivinkka, Huini Li, Ping Chen, Jorma Keski‐Oja, Marko M. Hyytiäinen · 2013 · PLoS ONE
  89. Temozolomide and oral VP‐16 for children and young adults with recurrent or treatment‐induced malignant gliomas
    David Nathan Korones, Amy Smith, Nicholas K. Foreman, Éric Bouffet · 2005 · Pediatric Blood & Cancer
  90. Phase I trial of dose-escalating metronomic temozolomide plus bevacizumab and bortezomib for patients with recurrent glioblastoma
    D. Jay McCracken, Emma Celano, Alfredo Daniel Voloschin, William L. Read, Jeffrey J. Olson · 2016 · Journal of Neuro-Oncology
  91. Salvage therapy with single agent bendamustine for recurrent glioblastoma
    Marc Charles Chamberlain, Sandra K. Johnston · 2011 · Journal of Neuro-Oncology
  92. Impact of p53 status to response of temozolomide in low MGMT expression glioblastomas: preliminary results
    Shouwei Li, Tao Jiang, Guilin Li, Zhongcheng Wang · 2008 · Neurological Research
  93. Enhancement of radiosensitivity in human glioblastoma cells by the DNA N-mustard alkylating agent BO-1051 through augmented and sustained DNA damage response
    Pei‐Ming Chu, Shih‐Hwa Chiou, Tsann‐Long Su, Yi‐Jang Lee, Li-Hsin Chen, Yi‐Wei Chen, Sang-Hue Yen, Ming-Teh Chen, Ming-Hsiung Chen, Yang‐Hsin Shih et al. · 2011 · Radiation Oncology
  94. Neuro-oncology, a decade of temozolomide and beyond
    Roger Stupp, Monika E. Hegi, Michael Weller · 2010 · Expert Review of Anticancer Therapy
  95. Temozolomide during and after radiation therapy for WHO grade III gliomas: preliminary report of a prospective multicenter study
    Young‐Hoon Kim, Chul‐Kee Park, Won Ho Cho, In Ah Kim, Seyoung Moon, Gheeyoung Choe, Sung‐Hye Park, Il Han Kim, Dong Gyu Kim, Hee‐Won Jung et al. · 2010 · Journal of Neuro-Oncology
  96. Safety and efficacy of depatuxizumab mafodotin in Japanese patients with malignant glioma: A nonrandomized, phase 1/2 trial
    Yoshitaka Narita, Yoshihiro Muragaki, Naoki Kagawa, Katsunori Asai, Motoo Nagane, Masahide Matsuda, Keisuke Ueki, Jun‐ichiro Kuroda, Isao Date, Hiroyuki Kobayashi et al. · 2021 · Cancer Science
  97. Role of bevacizumab therapy in the management of glioblastoma
    Victor A. Levin · 2010 · Cancer Management and Research
  98. Cost–effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme
    Carin A. Uyl‐de Groot, Roger Stupp, Martin J. van den Bent · 2009 · Expert Review of Pharmacoeconomics & Outcomes Research
  99. Risks and benefits with bevacizumab: evidence and clinical implications
    Carla D. Kurkjian, Edward S. Kim · 2011 · Therapeutic Advances in Drug Safety
  100. Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience
    Tanja Mesti, Maja Ebert Moltara, Marko Boc, Martina Reberšek, Janja Ocvirk · 2014 · Radiology and Oncology